Efficacy of atropine as an endoscopic premedication.
To determine the efficacy of atropine as an endoscopic premedication, we prospectively evaluated in double-blind fashion 196 elective endoscopies performed on 189 consecutive consenting patients. Group 1 (95 endoscopies) received meperidine, 1.5 mg/kg, intramuscularly 30 min prior to endoscopy. Group 2 (101 endoscopies) additionally received atropine, 0.6 mg, in the same injection. Endoscopy was performed by one of two investigators using a 13-mm fiberoptic instrument. Endoscopists and patients filled out postendoscopy questionnaires. Both endoscopists (p less than 0.01) and patients (p less than 0.05) noted less oral secretions after atropine. Endoscopists noted less gastric motility after atropine (p less than 0.05) and guessed correctly whether or not atropine had been given in two thirds of cases. They noted no overall difference, however, in the ease of the endoscopy (p greater than 0.05). Moreover, there were no differences in the patients' assessments of the acceptability of the procedure between the two groups (p greater than 0.05). We concluded that although atropine does not improve patients' tolerance for the examination or the endoscopists' ability to do an adequate examination, it does objectively decrease the amount of gastric motility and oral secretions. This latter effect could potentially decrease the hazard of aspiration, but such a benefit could not be demonstrated in our series.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001285:Atropine / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004724:Endoscopy / Q000523:psychology; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D008297:Male; D008614:Meperidine / Q000494:pharmacology; D008875:Middle Aged; D011292:Premedication; D011446:Prospective Studies; D012472:Salivation / Q000187:drug effects; D011795:Surveys and Questionnaires
D001285:Atropine; D008614:Meperidine